BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33543394)

  • 1. Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
    Volante M; Lam AK; Papotti M; Tallini G
    Endocr Pathol; 2021 Mar; 32(1):63-76. PubMed ID: 33543394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
    Nikiforov YE
    Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
    Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma: a possible manifestation of high-grade transformation.
    Amacher AM; Goyal B; Lewis JS; El-Mofty SK; Chernock RD
    Am J Surg Pathol; 2015 Feb; 39(2):260-5. PubMed ID: 25321328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Thyroid Pathology: High Grade Follicular Cell-derived Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein RA
    Adv Anat Pathol; 2023 Jan; 30(1):3-10. PubMed ID: 36306188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Insights of Thyroid Cancer Progression.
    Leandro-García LJ; Landa I
    Endocrinology; 2023 Aug; 164(9):. PubMed ID: 37503738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
    Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
    In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.
    Sasanakietkul T; Murtha TD; Javid M; Korah R; Carling T
    Mol Cell Endocrinol; 2018 Jul; 469():23-37. PubMed ID: 28552796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma.
    Zeng PYF; Prokopec SD; Lai SY; Pinto N; Chan-Seng-Yue MA; Clifton-Bligh R; Williams MD; Howlett CJ; Plantinga P; Cecchini MJ; Lam AK; Siddiqui I; Wang J; Sun RX; Watson JD; Korah R; Carling T; Agrawal N; Cipriani N; Ball D; Nelkin B; Rooper LM; Bishop JA; Garnis C; Berean K; Nicolson NG; Weinberger P; Henderson YC; Lalansingh CM; Tian M; Yamaguchi TN; Livingstone J; Salcedo A; Patel K; Vizeacoumar F; Datti A; Xi L; Nikiforov YE; Smallridge R; Copland JA; Marlow LA; Hyrcza MD; Delbridge L; Sidhu S; Sywak M; Robinson B; Fung K; Ghasemi F; Kwan K; MacNeil SD; Mendez A; Palma DA; Khan MI; Shaikh M; Ruicci KM; Wehrli B; Winquist E; Yoo J; Mymryk JS; Rocco JW; Wheeler D; Scherer S; Giordano TJ; Barrett JW; Faquin WC; Gill AJ; Clayman G; Boutros PC; Nichols AC
    Cell Rep; 2024 Mar; 43(3):113826. PubMed ID: 38412093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
    Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
    Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
    [No Abstract]   [Full Text] [Related]  

  • 17. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
    Ibrahimpasic T; Ghossein R; Shah JP; Ganly I
    Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
    Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
    Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
    Nikiforova MN; Kimura ET; Gandhi M; Biddinger PW; Knauf JA; Basolo F; Zhu Z; Giannini R; Salvatore G; Fusco A; Santoro M; Fagin JA; Nikiforov YE
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5399-404. PubMed ID: 14602780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.
    Xu B; David J; Dogan S; Landa I; Katabi N; Saliba M; Khimraj A; Sherman EJ; Tuttle RM; Tallini G; Ganly I; Fagin JA; Ghossein RA
    Histopathology; 2022 Jan; 80(2):322-337. PubMed ID: 34449926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.